Cancer & microbiome – impact on future diagnostic pathology

- Microbiota analysis is NGS based (available in pathology departments)
- Potential additional parameter for risk assessment/stratification (neoplasia, progression,...)
- Fecal microbiota linked to immune-checkpoint inhibitor therapy efficacy (treatment response)
- .........
Metagenomic signature in adenomas & CRC higher sensitivity & specificity than hemoccult (fecal occult blood) test for CRC detection
Cancer & microbiome – impact on future diagnostic pathology

F. nucleatum in SSAs

Yu et al Int J Cancer 2016

gregor.gorkiewicz@medunigraz.at
Signatures of efficacy of immune checkpoint inhibitor therapy
